NewEdge Advisors LLC Grows Position in Becton, Dickinson and Company $BDX

NewEdge Advisors LLC grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 35.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,032 shares of the medical instruments supplier’s stock after buying an additional 11,414 shares during the quarter. NewEdge Advisors LLC’s holdings in Becton, Dickinson and Company were worth $6,923,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company in the 3rd quarter worth $25,000. Steph & Co. boosted its stake in shares of Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares during the period. SHP Wealth Management bought a new position in shares of Becton, Dickinson and Company in the fourth quarter worth about $26,000. Meeder Asset Management Inc. grew its position in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares in the last quarter. Finally, Prosperity Bancshares Inc bought a new stake in Becton, Dickinson and Company during the 4th quarter valued at approximately $29,000. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,189 shares of company stock valued at $765,661 over the last ninety days. 0.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on BDX. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research note on Friday. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday. Finally, UBS Group assumed coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $185.00.

Becton, Dickinson and Company Stock Up 1.5%

Shares of NYSE:BDX opened at $179.57 on Tuesday. The company has a market cap of $49.48 billion, a price-to-earnings ratio of 54.09, a PEG ratio of 12.47 and a beta of 0.19. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average price of $155.05 and a 200 day moving average price of $162.03.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.